Correlation Between SAB Biotherapeutics and Collplant Biotechnologies

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Collplant Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Collplant Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SAB Biotherapeutics and Collplant Biotechnologies, you can compare the effects of market volatilities on SAB Biotherapeutics and Collplant Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Collplant Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Collplant Biotechnologies.

Diversification Opportunities for SAB Biotherapeutics and Collplant Biotechnologies

-0.69
  Correlation Coefficient

Excellent diversification

The 3 months correlation between SAB and Collplant is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Collplant Biotechnologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Collplant Biotechnologies and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Collplant Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Collplant Biotechnologies has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Collplant Biotechnologies go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Collplant Biotechnologies

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 4.29 times less return on investment than Collplant Biotechnologies. In addition to that, SAB Biotherapeutics is 6.43 times more volatile than Collplant Biotechnologies. It trades about 0.01 of its total potential returns per unit of risk. Collplant Biotechnologies is currently generating about 0.25 per unit of volatility. If you would invest  371.00  in Collplant Biotechnologies on September 4, 2024 and sell it today you would earn a total of  67.00  from holding Collplant Biotechnologies or generate 18.06% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy90.48%
ValuesDaily Returns

SAB Biotherapeutics  vs.  Collplant Biotechnologies

 Performance 
       Timeline  
SAB Biotherapeutics 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Collplant Biotechnologies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Collplant Biotechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

SAB Biotherapeutics and Collplant Biotechnologies Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with SAB Biotherapeutics and Collplant Biotechnologies

The main advantage of trading using opposite SAB Biotherapeutics and Collplant Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Collplant Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will offset losses from the drop in Collplant Biotechnologies' long position.
The idea behind SAB Biotherapeutics and Collplant Biotechnologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Complementary Tools

Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Money Managers
Screen money managers from public funds and ETFs managed around the world